It remains to be seen whether abelacimab is clinically effective for stroke prevention in people with atrial fibrillation ... a direct oral anticoagulant (DOAC), according to the AZALEA-TIMI ...

At 3 months, the median reduction in free factor XI levels with abelacimab at a dose of 150 ... as compared with the DOAC rivaroxaban among patients with atrial fibrillation and moderate-to ...

LOS ANGELES -- In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) -- though, as feared, ...

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

And this is common, about one-third of the patients with AFib will go through surgeries over the course of a year or 2 years. And so, typically, with the DOAC ... % in the high dose group ...

For people with atrial fibrillation (Afib), investigational ... lower safety risks compared with a direct oral anticoagulant (DOAC), according to the AZALEA-TIMI 71 trial. Testing two once-monthly ...